{Reference Type}: Journal Article
{Title}: Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary.
{Author}: Cluck DB;Chastain DB;Murray M;Durham SH;Chahine EB;Derrick C;Dumond JB;Hester EK;Jeter SB;Johnson MD;Kilcrease C;Kufel WD;Kwong J;Ladak AF;Patel N;Pérez SE;Poe JB;Bolch C;Thomas I;Asiago-Reddy E;Short WR;
{Journal}: Pharmacotherapy
{Volume}: 44
{Issue}: 5
{Year}: 2024 May
{Factor}: 6.251
{DOI}: 10.1002/phar.2913
{Abstract}: Treatment options are currently limited for persons with HIV-1 (PWH) who are heavily treatment-experienced and/or have multidrug-resistant HIV-1. Three agents have been approved by the U.S. Food and Drug Administration (FDA) since 2018, representing a significant advancement for this population: ibalizumab, fostemsavir, and lenacapavir. However, there is a paucity of recommendations endorsed by national and international guidelines describing the optimal use (e.g., selection and monitoring after initiation) of these novel antiretrovirals in this population. To address this gap, a modified Delphi technique was used to develop these consensus recommendations that establish a framework for initiating and managing ibalizumab, fostemsavir, or lenacapavir in PWH who are heavily treatment-experienced and/or have multidrug-resistant HIV-1. In addition, future areas of research are also identified and discussed in the main document.